Division of Hepatitis and Enterovirus Vaccines, Institute of Biological Products, National Institutes for Food and Drug Controlgrid.410749.f, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Beijing, People's Republic of China.
Institute of Medical Biology, Chinese Academy of Medicine Sciences & Peking Union Medical College, Kunming People's Republic of China.
Microbiol Spectr. 2022 Oct 26;10(5):e0226322. doi: 10.1128/spectrum.02263-22. Epub 2022 Sep 7.
We investigated the distribution, virulence, and pathogenic characteristics of mutated SARS-CoV-2 to clarify the association between virulence and the viral spreading ability of current and future circulating strains. Chinese rhesus macaques were infected with ancestral SARS-CoV-2 strain GD108 and Beta variant B.1.351 (B.1.351) and assessed for clinical signs, viral distribution, pathological changes, and pulmonary inflammation. We found that GD108 replicated more efficiently in the upper respiratory tract, whereas B.1.351 replicated more efficiently in the lower respiratory tract and lung tissue, implying a reduced viral shedding and spreading ability of B.1.351 compared with that of GD108. Importantly, B.1.351 caused more severe lung injury and dramatically elevated the level of inflammatory cytokines compared with those observed after infection with GD108. Moreover, both B.1.351 and GD108 induced spike-specific T-cell responses at an early stage of infection, with higher levels of interferon gamma (IFN-γ) and tumor necrosis factor alpha (TNF-α) in the B.1.351 group and higher levels of interleukin 17 (IL-17) in the GD108 group, indicating a divergent pattern in the T-cell-mediated inflammatory "cytokine storm." This study provides a basis for exploring the pathogenesis of SARS-CoV-2 variants of concern (VOCs) and establishes an applicable animal model for evaluating the efficacy and safety of vaccines and drugs. One of the priorities of the current SARS-CoV-2 vaccine and drug research strategy is to determine the changes in transmission ability, virulence, and pathogenic characteristics of SARS-CoV-2 variants. In addition, nonhuman primates (NHPs) are suitable animal models for the study of the pathogenic characteristics of SARS-CoV-2 and could contribute to the understanding of pathogenicity and transmission mechanisms. As SARS-CoV-2 variants continually emerge and the viral biological characteristics change frequently, the establishment of NHP infection models for different VOCs is urgently needed. In the study, the virulence and tissue distribution of B.1.351 and GD108 were comprehensively studied in NHPs. We concluded that the B.1.351 strain was more virulent but exhibited less viral shedding than the latter. This study provides a basis for determining the pathogenic characteristics of SARS-CoV-2 and establishes an applicable animal model for evaluating the efficacy and safety of vaccines and drugs.
我们研究了突变的 SARS-CoV-2 的分布、毒力和致病特征,以阐明毒力与当前和未来流行株病毒传播能力之间的关系。我们用中国恒河猴感染 SARS-CoV-2 的原始株 GD108 和 Beta 变体 B.1.351(B.1.351),并评估了临床症状、病毒分布、病理变化和肺部炎症。我们发现,GD108 在呼吸道的上部分布更有效,而 B.1.351 在呼吸道的下部分布和肺部组织中分布更有效,这表明与 GD108 相比,B.1.351 的病毒脱落和传播能力降低。重要的是,B.1.351 引起的肺部损伤比感染 GD108 后更严重,炎症细胞因子水平显著升高。此外,B.1.351 和 GD108 在感染早期都诱导了刺突特异性 T 细胞反应,B.1.351 组中干扰素γ(IFN-γ)和肿瘤坏死因子-α(TNF-α)水平更高,而 GD108 组中白细胞介素 17(IL-17)水平更高,表明 T 细胞介导的炎症“细胞因子风暴”存在不同的模式。本研究为探索 SARS-CoV-2 变异株(VOCs)的发病机制提供了依据,并建立了评估疫苗和药物疗效和安全性的适用动物模型。 当前 SARS-CoV-2 疫苗和药物研究策略的重点之一是确定 SARS-CoV-2 变异株的传播能力、毒力和致病特征的变化。此外,非人类灵长类动物(NHPs)是研究 SARS-CoV-2 致病特征的合适动物模型,可以帮助了解致病性和传播机制。随着 SARS-CoV-2 变异株的不断出现,病毒的生物学特性经常发生变化,因此迫切需要建立针对不同 VOC 的 NHP 感染模型。在本研究中,我们全面研究了 B.1.351 和 GD108 在 NHPs 中的毒力和组织分布。我们得出的结论是,B.1.351 株的毒力更强,但病毒脱落量比后者少。本研究为确定 SARS-CoV-2 的致病特征提供了依据,并建立了评估疫苗和药物疗效和安全性的适用动物模型。